Modulation of methylglyoxal-triggered oxidative damage and apoptosis in human osteoblasts by metformin, berberine, and genistein
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Bone fragility in diabetes is linked to redox imbalance and advanced glycation end products (AGEs). Methylglyoxal (MGO), a reactive carbonyl compound and precursor of AGEs, complicates the pathogenesis of diabetes mellitus and oxidative stress. Metformin lowers the AGEs level. Genistein and berberine decrease MGO levels and inhibit AGE formation. This study investigates the individual and combinatorial effects of metformin, berberine, and genistein on osteoblast-treated MGO in terms of apoptosis and oxidative stress. Human foetal osteoblast cells (hFOB 1.19) were incubated with MGO for 24 hours and treated with metformin, berberine, genistein, and combinations of these compounds. The cells were assessed for apoptosis, AGE levels, oxidative stress markers, and the polymerization status of actin and tubulin fibers. Incubation with metformin, berberine, or genistein alone showed that these compounds significantly reduced apoptotic cells (26.16%, 31.83%, and 41.83%, respectively) compared to MGO alone(p
Fields of Study & Subjects
Advanced Glycation End Products research
Bone Metabolism and Diseases
Metabolism
Diabetes
and Cancer
Publication details
- Journal / source
- Asia-Pacific Journal of Molecular Biology and Biotechnology
- Pages
- 155–155
- Publication date
- 28 March 2026
- Language
- EN